BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
Monday, 2nd December at 7:50 am The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune check point inhibitor in metastatic breast cancer The pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration (FDA)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more